Justin Anderson, MD
Cardiovascular Disease · Lynchburg, VANPI 1922188523
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,464 of the $1,780 with a category attached, or 82.2%. Heartflow, Inc. accounts for 89.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $1,464 and has fallen 88.2% since, to $173 in 2025.
Across 15 payments — averaging $118.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$2K
- Cardiva Medical, Inc.$74
- Boston Scientific$39
- Astellas Pharma US Inc$25
- Amgen$22
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17
- plus $12 from 1 others
What the payments were for
- Travel & lodging$1,46482%
- Food & beverage$30417%
- Education$121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 8 | $1,590 |
| Cardiva Medical, Inc. | 2 | $74 |
| Boston Scientific | 1 | $39 |
| Astellas Pharma US Inc | 1 | $25 |
| Amgen | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
How this compares
$1,780 in reported general payments places this provider in the 55th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 258 | $244,487 |
| XareltoRivaroxaban | 50 | $50,523 |
| FarxigaDapagliflozin Propanediol | 31 | $41,636 |
| EntrestoSacubitril/Valsartan | 20 | $33,537 |
| Repatha SureclickEvolocumab | 40 | $32,979 |
| Praluent PenAlirocumab | 45 | $25,411 |
| JardianceEmpagliflozin | 16 | $17,055 |
| BrilintaTicagrelor | 11 | $4,845 |
| Atorvastatin Calcium | 281 | $2,529 |
| Prasugrel Hcl | 11 | $2,237 |
| Rosuvastatin Calcium | 186 | $1,805 |
| Metoprolol Succinate | 116 | $1,498 |
| Carvedilol | 172 | $1,441 |
| Amlodipine Besylate | 282 | $1,319 |
| Metoprolol Tartrate | 244 | $1,249 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lynchburg
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
- Christopher OconnorFalls Church$161K
- Roberta ChapmanGloucester$155K
- Shaival KapadiaColonial Heights$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.